Thursday, October 8, 2026
ExploreSearch
Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· July 10, 2026

Pepeto Passes $10.4 Million While the BNB Price Prediction Target $2,000 As Best Crypto To Buy

View original at globenewswire.com
Pepeto Passes $10.4 Million While the BNB Price Prediction Target $2,000 As Best Crypto To Buy DUBAI, United Arab Emirates, July 10, 2026 (GLOBE NEWSWIRE) -- Crypto presale Pepeto moved past $10.431 million, and traction like that in a red market raises one question…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Pepeto sits first among crypto presales this year by capital raised, following the exchange token model.

    60% confidence

  • Pepeto built a zero-fee exchange running on its own token, plus a cross-chain bridge linking Ethereum, BNB Chain, and Solana with no gas cost.

    60% confidence

  • Pepeto has 420 trillion tokens priced at $0.0000001881, with 30% of supply allocated to presale tokens; a climb to a $300 million market cap would mean roughly 50x, turning $5,000 into $250,000, and matching PEPE's peak would push well past 100x.

    60% confidence

  • BNB is trading near $577.

    60% confidence

  • Early BNB buyers entered the 2017 ICO at $0.10 per token when it had barely any market value.

    60% confidence

  • The top BNB price prediction for a full bull cycle is $2,060.

    60% confidence

  • A run from $577 to $2,000 for BNB is about a 3.5x return, turning $1,000 into roughly $3,500.

    60% confidence

Data points we hold from this source

Pepeto · token price0.0000001881 USD
Pepeto · funding raised10.41 USD
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Autumn 2026 Biopharma Catalyst Season: Late-Breaking Data, FDA Milestones and the Rise of AI-Designed Drugs
Late-September and early-October 2026 conferences (EASD, EADV, IGCS) brought a cluster of positive late-breaking trial readouts. These covered obesity and metabolic disease (Novo Nordisk's CagriSema), immunology (Lilly's EBGLYSS, tulisokibart) and oncology (Rina-S, Agenus BOT+BAL). Ahead lie hard regulatory catalysts, led by the 14 Nov 2026 FDA PDUFA date for ivonescimab. At the same time, Insilico-style AI-designed drugs such as rentosertib are showing anti-aging signals. That points to AI-driven drug discovery moving from concept toward clinical validation. Unrelated tech and regulatory items (Tesla Cybercab probe, xAI litigation, OpenAI agent incident) and the speculative QAIAx claims are peripheral to this story.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,362 source documents archived
Query this data → isubstrate.com
Pepeto Passes $10.4 Million While the BNB Price Prediction Target $2,000 As Best Crypto To Buy — Source | Via News | ViaNews Market